Global Swine Flu Drugs Market: Overview
Swine flu is a respiratory disease originally transmitted from pigs to human beings, and presently even from one person to another. Symptoms of swine flu include vomiting, nausea, sore throat, runny nose, sneezing, coughing, diarrhea, chills, headaches, lethargy, fever, and lack of appetite. Swine flu cases become more prevalent during monsoon and summer seasons.
People with weak or compromised immune systems, heart problems, or and diabetics, besides pregnant women and children, are at high-risk of swine flu. The incubation period of swine flu is approximately one day to four days. Diagnosis of swine flu is done in labs through the identification of antigens specifically associated with the H1N1 type A influenza virus. Drugs available for the treatment of swine flu include Tamiflu, Oseltamivir, Relenza, Zanamivir, and Peramivir. However, among swine flu drugs, Peramivir has not been approved by the FDA for the treatment of swine flu.
Obtain Report Details @ https://www.transparencymarketresearch.com/swine-flu-drugs-market.html
Global Swine Flu Drugs Market: Drivers and Restraints
Swine flu virus was for the first time isolated from pigs in the U.S. in 1930 and has been recognized to have caused infections among pigs all over the world. People who are closely associated with pigs, such as pork processors or farmers, tend to get affected with swine flu drugs. In many cases swine flu drugs cross infections that is human flu virus to pigs or swine virus to human beings has remained in the local areas. However, in Mexico, in April 2009, there was an outbreak (pandemic) of swine flu due to infection with the H1N1 virus.
The term H1N1 flu was coined by the investigators as it was mainly found infecting human beings and exhibited two main surface antigens, H1 (hem agglutinin type 1) and N1 (neuraminidase type1). Swine flu has been spreading all over the world. Increase in prevalence of swine flu drives the growth of the swine flu drugs market. In Asia, for instance, India recorded approximately 1,094 deaths in 2017 caused by swine flu, as per a BBC news report. The report also stated that there were a total of 22,186 cases of swine flu testified across India.
Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41309
Global Swine Flu Drugs Market: Key Segments
The swine flu drugs market can be segmented on the basis of drug class, dosage form, distribution channel, and region. Based on drug class, the swine flu drugs market can be categorized into neuraminidase inhibitors and inhaled anti-infectives. In terms of dosage form, the swine flu drugs market can be classified into capsule and oral powder inhalation. Based on distribution channel, the swine flu drugs market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies segment was estimated to dominate the swine flu drugs market in 2016 owing to the wide availability of swine flu drugs in them.
Geographically, the swine flu drugs market can be divided into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. Asia Pacific accounted for the dominant swine flu drugs market share in 2016 due to increase in prevalence of swine flu in the region. Europe constituted the next leading share of the swine flu drugs market in 2016 owing to rise in infectious diseases among people with certain long-term health conditions, pregnant women, young children, and geriatric population. North America also held a significant share of the swine flu drugs market in 2016, due to increasing prevalence of the swine flu in the region. The swine flu drugs market in Middle East & Africa and Latin America is anticipated to expand during the forecast period.
Global Swine Flu Drugs Market: Key Players
Key players operating in the swine flu drugs market include Gilead Sciences, Inc., Genentech, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline, and BioCryst Pharmaceuticals, Inc.